NEW DELHI: The Haemophilia & Health Collective of North (HHCN), a nationally registered body comprising senior doctors from across India, organized a landmark conference titled “The Inhibitors Colloquium 2025” at Aerocity, New Delhi.
Held under the theme “Driving Innovation: A New Era of Haemophilia Management,” the event aimed to spotlight recent advances in haemophilia care and address ongoing challenges in its treatment.
The conference brought together a distinguished gathering of medical professionals including haematologists, paediatricians, physicians, pathologists, and experts in laboratory medicine from premier institutions such as AIIMS, PGI Chandigarh, MAMC, Lady Hardinge, VMMC & Safdarjung Hospital, KGMU Lucknow, GMC Srinagar, and others. It also featured the presence of officials from the National Health Mission (NHM) and faculty from across India.
A major highlight of the event was the participation of Prof. Johny Mahlangu, Director of the Haemophilia Comprehensive Care Centre at University Hospital, Johannesburg, South Africa. Prof. Mahlangu, also President of the South African Society of Haematology and the South African Medical Association, delivered an insightful lecture on rebalancing haemostasis using anti-TFPI therapies, such as mAb2021.
He also participated in a panel discussion on Non-Factor Therapies (NFTs) and their clinical application.
Dr. Kuldeep Kumar Kaul, President of HHCN and former Professor & Head, Department of Pathology, GMC Jammu, inaugurated the conference and welcomed the delegates. In his keynote address, Dr. Kaul spoke about transformative developments in haemophilia treatment over the past decade, particularly in non-factor therapies like Emicizumab, used for Haemophilia A patients with or without inhibitors. He also discussed upcoming innovations such as Concizumab and Fitusiran, highlighting their potential as haemostatic rebalancing agents. However, he also stressed the challenges these therapies pose, including laboratory monitoring issues, management of breakthrough bleeds, and ensuring equitable access.
Dr. Naresh Gupta, Chairperson of HHCN and former Director-Professor of Medicine at MAMC, provided an overview of HHCN’s initiatives and moderated a dynamic panel on addressing the aspirations of people with haemophilia. He emphasized the need for policy alignment, innovation, and outreach to ensure quality care for all patients.
Other key sessions covered a wide range of topics such as evolving lab practices for NFTs, unmet needs in treatment delivery, limitations of current therapies, and the transition from vial-based treatments to pen-based administration. The conference also discussed how innovation is reshaping the landscape of haemophilia care in India.
The event reflects HHCN’s ongoing commitment to high-quality and accessible haemophilia care. Notably, the organization recently held the Haemophilia Summit in Leh and Kargil as part of the “Ladakh Health Dialogue 2025,” with full support from the UT Administration of Ladakh.
In his concluding remarks, Dr. Kaul reaffirmed HHCN’s mission to ensure “Treatment for all, One country one treatment, and a disability-free future for people with haemophilia.”
The conference ended with a vote of thanks and closing remarks by Dr. Naresh Gupta, who praised the efforts of all participants in advancing the collective goal of improved haemophilia care in India.
